SynthesisFrontiers in endocrinology2025
The impact of Jinlida on blood glucose control and insulin resistance in patients with prediabetes and type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of Jinlida (JLD) in improving glycemic control and insulin resistance in patients with prediabetes (PD) and type 2 diabetes mellitus (T2DM) through a meta-analysis of randomized controlled trials (RCTs). Methods: Databases including PubMed, Web of Science, Cochrane Library, Embase, Scopus, CBM, CNKI, Wanfang, and VIP were searched up to July 2025. Randomized controlled trials comparing JLD with controls were included. Pooled analyses were conducted using a random-effects model. Pre-specified subgroup analyses included health status and treatment duration. Additional analyses by baseline FBG level and age were performed to explore residual heterogeneity. Multivariable meta-regression with Knapp-Hartung adjustment further examined potential moderators (e.g., background therapy, baseline FBG level). Publication bias was assessed by funnel plots, Egger's test, and the trim-and-fill method. Risk of bias and evidence certainty were evaluated using RoB 2.0 and GRADE. Results: A total of 20 RCTs involving 2,993 participants were included. Compared with controls, JLD significantly reduced: FBG (MD = -0.97, 95% CI: -1.40 to -0.53; Conclusion: JLD may help improve glycemic control, insulin resistance, and lipid profiles in patients with T2DM and prediabetes. Given the varying levels of certainty in the evidence across outcomes, these findings should be interpreted cautiously. Further large-scale, high-quality RCTs are needed to confirm these findings. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251124510.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.